CMMB Chemomab Therapeutics Ltd Forecast, Technical & Fundamental Analysis
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs... Show more
CMMB is expected to report earnings to rise 233.33% to 0 cents per share on August 07
Q2'26
Est.
$-0.01
Q1'26
Beat
by $0.01
Q4'25
Missed
by $0.23
Q3'25
Missed
by $0.31
Q2'25
Beat
by $0.08
The last earnings report on May 14 showed earnings per share of 0 cents, beating the estimate of 0 cents. With 12.38K shares outstanding, the current market capitalization sits at 12.96M.
A.I.dvisor indicates that over the last year, CMMB has been loosely correlated with TNYA. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if CMMB jumps, then TNYA could also see price increases.
CMMB's RSI Indicator recovers from overbought zone
The 10-day RSI Oscillator for CMMB moved out of overbought territory on May 27, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 instances where the indicator moved out of the overbought zone. In of the 20 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on June 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CMMB as a result. In of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for CMMB turned negative on June 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CMMB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CMMB broke above its upper Bollinger Band on May 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
CMMB moved above its 50-day moving average on May 21, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CMMB crossed bullishly above the 50-day moving average on May 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CMMB advanced for three days, in of 216 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 88 cases where CMMB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.212) is normal, around the industry mean (18.403). P/E Ratio (0.000) is within average values for comparable stocks, (36.362). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.686). CMMB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.039). P/S Ratio (0.000) is also within normal values, averaging (356.365).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CMMB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CMMB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
